The anaplastic lymphoma kinase in the pathogenesis of cancer (Q37039605)

17 August 2017

title

The anaplastic lymphoma kinase in the pathogenesis of cancer (English)

1 reference

17 August 2017

0 references

1

Roberto Chiarle

0 references

Giorgio Inghirami

series ordinal

5

object named as

Giorgio Inghirami

1 reference

17 August 2017

2

Claudia Voena

1 reference

17 August 2017

3

Chiara Ambrogio

0 references

Roberto Piva

object named as

Roberto Piva

series ordinal

4

0 references

publication date

1 January 2008

1 reference

17 August 2017

language of work or name

English

0 references

published in

Nature Reviews Cancer

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

11-23

1 reference

publication type of scholarly work

17 August 2017

review article

1 reference

Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma

cites work

1 reference

The t(2;5) in Human Lymphomas

31 March 2020

1 reference

T-cell non-Hodgkin lymphoma

31 March 2020

1 reference

Peripheral T-cell lymphomas

31 March 2020

1 reference

CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35.

31 March 2020

1 reference

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

31 March 2020

1 reference

Anaplastic Large Cell Lymphoma.

31 March 2020

1 reference

Molecular variant of the NPM-ALK rearrangement of Ki-1 lymphoma involving a cryptic ALK splice site

31 March 2020

1 reference

Nucleophosmin/B23 (NPM) oligomer is a major and stable entity in HeLa cells

31 March 2020

1 reference

Formation of nucleophosmin/B23 oligomers requires both the amino- and the carboxyl-terminal domains of the protein

31 March 2020

1 reference

Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis

31 March 2020

1 reference

31 March 2020

Nucleophosmin and cancer

1 reference

Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity

31 March 2020

1 reference

ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).

31 March 2020

1 reference

Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma

31 March 2020

1 reference

Centrosome abnormalities in ALK-positive anaplastic large-cell lymphoma

31 March 2020

1 reference

TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins.

31 March 2020

1 reference

The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells

31 March 2020

1 reference

Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals

31 March 2020

1 reference

Transcription of AML1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia

31 March 2020

1 reference

Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells

31 March 2020

1 reference

Oncogene-induced senescence as an initial barrier in lymphoma development

31 March 2020

1 reference

Overexpression of NPM–ALK induces different types of malignant lymphomas in IL-9 transgenic mice

31 March 2020

1 reference

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

31 March 2020

1 reference

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target

31 March 2020

1 reference

What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?

31 March 2020

1 reference

Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase

31 March 2020

1 reference

Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines

31 March 2020

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

31 March 2020

1 reference

Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer.

31 March 2020

1 reference

TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors

31 March 2020

1 reference

Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases

31 March 2020

1 reference

Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor

31 March 2020

1 reference

Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor

31 March 2020

1 reference

Expression of the ALK tyrosine kinase gene in neuroblastoma

31 March 2020

1 reference

Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth

31 March 2020

1 reference

In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?

31 March 2020

1 reference

Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types

31 March 2020

1 reference

Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation

31 March 2020

1 reference

ALK protein expression in rhabdomyosarcomas

31 March 2020

1 reference

Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer

31 March 2020

1 reference

Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma

31 March 2020

1 reference

The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up‐regulation in rat la fibroblasts

31 March 2020

1 reference

p130Cas mediates the transforming properties of the anaplastic lymphoma kinase

31 March 2020

1 reference

Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity

31 March 2020

1 reference

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

31 March 2020

1 reference

The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas.

31 March 2020

1 reference

Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)

31 March 2020

1 reference

Anaplastic lymphoma kinase proteins in growth control and cancer

31 March 2020

1 reference

The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration

31 March 2020

1 reference

Critical role for Gab2 in transformation by BCR/ABL

31 March 2020

1 reference

Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity

31 March 2020

1 reference

Activation of alpha-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase

31 March 2020

1 reference

SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling

31 March 2020

1 reference

Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma

31 March 2020

1 reference

Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma

31 March 2020

1 reference

NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.

31 March 2020

1 reference

Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA)

31 March 2020

1 reference

Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1.

31 March 2020

1 reference

NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry

31 March 2020

1 reference

NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a

31 March 2020

1 reference

Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma

31 March 2020

1 reference

Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma

31 March 2020

1 reference

Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.

31 March 2020

1 reference

Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo

31 March 2020

1 reference

Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

31 March 2020

1 reference

Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells

31 March 2020

1 reference

STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression

31 March 2020

1 reference

Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma

31 March 2020

1 reference

NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner.

31 March 2020

1 reference

Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.

31 March 2020

1 reference

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

31 March 2020

1 reference

Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells

31 March 2020

1 reference

ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth

31 March 2020

1 reference

The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma

31 March 2020

1 reference

Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.

31 March 2020

1 reference

Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling

31 March 2020

1 reference

Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3

31 March 2020

1 reference

FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma

31 March 2020

1 reference

The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner

31 March 2020

1 reference

JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma

31 March 2020

1 reference

Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells

31 March 2020

1 reference

CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells

31 March 2020

1 reference

Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma

31 March 2020

1 reference

Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas

31 March 2020

1 reference

Gene expression profiling in anaplastic large cell lymphoma and Hodgkin's disease

31 March 2020

1 reference

Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes

31 March 2020

1 reference

Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets

31 March 2020

1 reference

Immunoaffinity profiling of tyrosine phosphorylation in cancer cells

31 March 2020

1 reference

Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins

31 March 2020

1 reference

Identification of NPM-ALK interacting proteins by tandem mass spectrometry.

31 March 2020

1 reference

Mass spectrometry-based proteomic studies of human anaplastic large cell lymphoma

31 March 2020

1 reference

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma

31 March 2020

1 reference

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

31 March 2020

1 reference

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells

31 March 2020

1 reference

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

31 March 2020

1 reference

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas

31 March 2020

1 reference

B and CTL responses to the ALK protein in patients with ALK-positive ALCL

31 March 2020

1 reference

Vaccines for tumour prevention

31 March 2020

1 reference

Strategies for silencing human disease using RNA interference

31 March 2020

1 reference

Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion.

31 March 2020

1 reference

Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers.

31 March 2020

1 reference

Anterograde Jelly belly and Alk receptor tyrosine kinase signaling mediates retinal axon targeting in Drosophila.

31 March 2020

1 reference

An SCF-like ubiquitin ligase complex that controls presynaptic differentiation

31 March 2020

1 reference

Characterization of the expression of the ALK receptor tyrosine kinase in mice

31 March 2020

1 reference

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

31 March 2020

1 reference

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

31 March 2020

1 reference

Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway

31 March 2020

1 reference

A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells

31 March 2020

1 reference

The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK.

31 March 2020

1 reference

Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin

31 March 2020

1 reference

Pleiotrophin is a neurotrophic factor for spinal motor neurons.

31 March 2020

1 reference

Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage.

31 March 2020

1 reference

Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin.

31 March 2020

1 reference

Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines

31 March 2020

1 reference

Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies

31 March 2020

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

31 March 2020

1 reference

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

31 March 2020

1 reference

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

31 March 2020

1 reference

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

31 March 2020

1 reference

FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity

31 March 2020

1 reference

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

31 March 2020

1 reference

A Case of a Diffuse Large B-Cell Lymphoma of Plasmablastic Type Associated With the t(2;5)(p23;q35) Chromosome Translocation

31 March 2020

1 reference

ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases

31 March 2020

1 reference

Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor

31 March 2020

1 reference

ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature

31 March 2020

1 reference

Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma

31 March 2020

1 reference

Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4--anaplastic lymphoma kinase gene fusion

31 March 2020

1 reference

Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor

31 March 2020

1 reference

Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma

31 March 2020

1 reference

Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3' ALK gene insertion to chromosome 4 q22-24

31 March 2020

1 reference

Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2291

1 reference

Dimensions Publication ID

17 August 2017

1017311282

0 references

1 reference